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The aim of this study was to investigate the early CD4+ T cell response among human
immunodeficiency virus type 1 (HIV-1) seroconverters in relation to their year of serocon-
version. Study participants were enrolled in the Swiss HIV Cohort Study between 1985 and
1995 and had not received antiretroviral treatment. The slope of the CD4+ T cell count within
2 years after seroconversion was significantly associated with the year of seroconversion, by
sex and by use of injection drugs, when controlling for initial CD4+ cell count. These results
show that the loss of CD4+ cells might be associated with the year of seroconversion, suggesting
a change in the pathogenesis of HIV across the years. If these results are confirmed, they
could have important implications for the pathogenesis of and therapeutic strategies for HIV-
1 infection.
CD41 T cell count is associated with human immunodefi-
ciency virus type 1 (HIV-1) disease progression and survival [1,
2] among patients infected by HIV from an unknown date and
among seroconverters [3, 4]. Recently, the prognostic value of
the CD41 cell count was confirmed independently of the virus
load [5]. Two studies done in the US Navy reported that
the initial CD41 cell count was !500/mm3 in nearly 40% and
!200/mm3 in nearly 4% of HIV-1 seroconverters 1 year after
seroconversion [6, 7]. These results suggest that host or viral
factors (or both) are associated with a faster loss of CD41 cells
early in the course of HIV infection. The emergence of more
virulent strains has also been suggested as a factor influencing
the rate of CD41 cell loss. Holmberg et al. [8] did not find that
recently infected persons lost their CD41 cells faster by year of
seroconversion, and this finding was confirmed among patients
from the Multicenter AIDS Cohort Study [9]. In addition, no
major change, such as a more rapid loss of CD41 T cells, seems
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to have occurred in the natural history of HIV-1 infection in
US patients.
In Europe, analysis of data from the Italian Seroconversion
Study [10] did not show a secular trend by year of serocon-
version for the initial CD41 cell measurement obtained within
24 months of seroconversion. Keet et al. [11] suggested a pro-
longation of the AIDS-free period for patients in the Amster-
dam Cohort Study, a finding in contrast to those from the
Tricontinental Seroconverters Study, which showed a more
rapid progression to AIDS in homosexual men who serocon-
verted between 1982 and 1987 [12]. In addition, Sinicco et al.
[13] showed that HIV-1 seroconversion after 1989 was an in-
dependent predictor of disease progression.
Additional studies are needed of the natural history of HIV-
1 infection for regional public health interventions and com-
parisons between countries. The Swiss HIV Cohort Study
(SHCS) provides an opportunity for such investigation [14, 15].
We studied the slope of CD41 cell decrease among HIV sero-
converters enrolled in SHCS between 1985 and 1995, to identify
any association between the loss of CD41 cells and the year of
seroconversion.
Methods
Study population. The SHCS is a prospective study based on
voluntary participation of persons infected by HIV-1; persons in-
fected by HIV-2 were not included. The rationale of the study, the
organization of the study, and the baseline characteristics of the
SHCS have been described in detail elsewhere [14, 15]. In brief,
this multicenter project was implemented in 7 university hospitals
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in Switzerland: Basel, Bern, Geneva, Lausanne, Lugano, St-Gall,
and Zurich. Study participants are from both sexes, belong to var-
ious groups at risk for HIV infection, and have a physical and
blood sample examination every 6 months.
In the first part of the study, we investigated HIV seroconverters
with a lag time for seroconversion of !12 months ( ). Then = 266
lag time for seroconversion was defined as the time elapsed between
the last HIV-negative screening test and the first HIV-positive
screening test. The date of infection was estimated as the midpoint
between these 2 tests, to facilitate comparisons with other inves-
tigations [9, 10].
To determine secular trends for the initial CD41 cell measure-
ment by year of seroconversion, we compared the first count among
patients after stratification by the year of seroconversion. This ap-
proach is similar to that of Galai et al. [10], except that we restricted
the lag time of the first CD41 cell determination to 1 year after
the date of HIV seroconversion, whereas Galai et al. used 2 years.
The lag time for the initial CD41 cell measurement was the time
elapsed from the estimated date of infection to the first CD41 cell
measurement. The mean lag time of the first CD41 cell determi-
nation was 5.6 months (median, 5.5 months; months).SD = 2.9
No patient had received antiretroviral therapy before the first CD41
cell count.
In the second part of the study, we estimated secular trends of
CD41 cell slopes within 2 years after HIV seroconversion. To do
this, we restricted the study population to patients with at least 4
CD41 cell determinations within 2 years since the date of HIV
seroconversion ( ). This inclusion criterion was chosen so thatn = 69
there would be enough reliable data for assessing a slope. To ex-
plore the natural history of CD41 cell response early after HIV
infection, we analyzed data from persons who did not receive any
antiretroviral drug during the 2 years after seroconversion or whose
treatment began !30 days before the last CD41 cell measurement
(1 month of treatment is unlikely to have an effect on the CD4
cell count).
Laboratory methods. HIV seroconversion was assessed by
ELISA, and Western blot was used to confirm the presence of HIV-
1 antibodies. CD41 cell counts were done similarly in each center
[16]. All participating centers used cytofluorometry and fluorescein
isothiocyanate– or phycoerythrin-labeled antibodies.
Statistical analysis. The baseline characteristics of the patient
population were reported by use of means, medians, and SDs for
continuous variables and percentages and frequencies for categor-
ical variables.
In the first part of the study ( ), we performed one-wayn = 266
analyses of variance (ANOVA) to compare age, CD41 cell count,
lag time for seroconversion, and lag time for the first CD41 cell
count by year of seroconversion. The x2 test was used to compare
sex and risk factors of HIV-infection distributions. The proportions
of patients having baseline CD41 cell counts !500/mm3,
!350/mm3, and !200/mm3 by year of seroconversion were compared
by use of the x2 test for trend [17].
In the second part of this study ( ), we analyzed individualn = 69
repeated measures of CD41 cell counts, to identify a secular trend
of these values over the years. We have included in the analysis
the data of persons with at least 4 determinations within 2 years
from seroconversion, with at least 2 measurements in the first year
and 2 in the second year. The analysis was done in 2 steps. First,
the slopes of the CD41 cell counts, with respect to time, were
estimated for each patient. In the second step, these slopes were
entered as dependent variables in a linear regression model in-
cluding years of seroconversion and adjusted for center, age, sex,
risk factors, initial CD41 cell count, time elapsed between the se-
roconversion and the first CD41 cell count, and the following fac-
tors in relation to years since seroconversion: center 3 year of
seroconversion, age 3 year of seroconversion, sex 3 year of se-
roconversion, and risk factors 3 year of seroconversion. We used
a backward stepwise method to identify the appropriate model. To
check the adequacy of the model and to identify influential cases,
studentized deleted residuals, leverages, and Cook distances were
computed. The statistical analyses were done by use of SPSS (ver-
sion 6.1; SPSS, Chicago) and Epi Info (version 6.04; Centers for
Disease Control and Prevention, Atlanta). was consideredP ! .05
statistically significant.
Results
First part of study. A total of 266 patients were included
in the first part of the study: 181 were male (68%), 93 (35%)
were exposed to HIV by homosexual contact, 86 (32%) were
exposed by heterosexual contact, 42 (16%) were exposed by
injection drug use (IDU), and 45 (17%) were exposed by sexual
contact and IDU or by another route. The mean age was
years (range, 17–60; median, 28.0).30.3 5 8.7
The overall median lag time for seroconversion was 6.0
months (range, 0.2–12.0), and the median lag time for the first
CD41 cell measurement was 5.5 months (range, 0.1–11.7). The
baseline characteristics did not differ by center (data not
shown). The overall median of the first CD41 cell count after
seroconversion was 546/mm3 (range, 4–2100/mm3). The overall
proportions of patients with CD4 cell counts !500/mm3, !350/
mm3, and !200/mm3 were 38.6%, 20.1%, and 3.6%, respectively.
Age, median lag times, and characteristics of CD41 cell
counts, by calendar year of seroconversion, are shown in table
1. There were no statistically significant differences for age, lag
for seroconversion, lag for CD41 cell measurement, and CD41
cell counts between years of seroconversion. Similarly, sex and
risk factor distributions did not show statistically significant
differences among years of seroconversion (data not shown).
The x2 tests for linear trend of these proportions, by year of
seroconversion, were not statistically significant.
Second part of study. Sixty-nine patients were included in
the second part of the study (table 2): 71% were male, 43.5%
were exposed to HIV by homosexual contact, 29% were ex-
posed by heterosexual contact, 12% were exposed by IDU, and
16% were exposed by other routes. The mean age was
years (range, 18–60). ANOVA was done on the31.6 5 10.4
initial CD41 cell counts, to identify possible differences among
years of seroconversion; the results were nonsignificant (P =
). In addition, there was no difference in the lag time for.42
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<1987 11 27.0 5.08 7.11 600 721 (400) 27 18 0
1988 29 28.0 5.50 6.59 540 676 (410) 34 14 7
1989 50 26.5 6.29 5.49 540 617 (350) 36 24 12
1990 40 26.0 4.81 4.85 528 518 (270) 45 32 15
1991 36 28.0 5.13 5.42 519 627 (300) 42 14 3
1992 39 29.5 6.21 5.96 571 615 (370) 28 18 15
1993 21 32.0 6.22 5.40 740 712 (279) 33 5 0
1994 19 35.0 8.95 6.85 560 684 (300) 26 16 0
1995 21 31.0 6.65 5.01 450 435 (230) 62 38 14
Total 266 28.0 6.01 5.49 546 612 (330) 38.6 20.1 3.6
NOTE. Represents first part of current study. HIV, human immunodeficiency virus.
a Time midpoint between last HIV-negative and first HIV-positive ELISA.
b Time between estimated date of infection and date of first CD41 T cell count.
c , x2 for linear trend.P = .42
d , x2 for linear trend.P = .83
e , x2 for linear trend.P = .98
Table 2. Descriptive statistics of the 4 CD41 cell determinations performed within 2 years of seroconversion among 69 participants of the Swiss
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<1987 (5) 562.0 7.43 676.0 6.66 693.0 16.05 649.6 23.40
1988 (5) 682.2 6.51 637.6 4.30 558.4 16.56 514.8 21.98
1989 (16) 646.2 5.75 657.2 6.35 503.1 16.57 531.3 20.07
1990 (9) 542.3 3.26 455.1 4.80 390.9 15.70 330.5 20.43
1991 (8) 652.3 5.08 555.2 5.12 480.4 15.12 508.0 18.40
1992 (14) 766.1 6.15 882.6 4.08 594.1 16.53 568.6 21.02
1993 (8) 871.8 5.97 608.1 5.43 673.5 17.25 599.1 21.39
1994 1 1995 (4) 801.3 3.96 756.7 6.10 633.3 16.10 590.7 20.33
NOTE. Represents second part of current study. Statistical level of significance of differences of CD41 cell counts at 6, 12, 18, and 24 months between patients
grouped by year of seroconversion are , .08, .07, and .46, respectively.P = .42
a Time elapsed between estimated date of seroconversion and initial measure of CD41 cells.
b Time elapsed between date of initial measurement of CD41 cells and every other count.
seroconversion ( ) or the lag time for the first CD41 cellP = .60
measurement by year of seroconversion ( ).P = .14
The overall mean of the individual CD41 cell count slopes
was 246 cells/mm3 per semester. The results of the statistical
analysis relating individual CD41 cell count slopes to prog-
nostic factors are shown in table 3. The initial CD41 cell count
was strongly associated with the slope ( ): the higherP = .001
the initial count, the steeper the negative slope. As an example,
an increase of 100 cells/mm3 for the initial count was associated
with a supplementary loss of 9.4 cells/mm3 per semester.
There were 2 significant interactions: year of seroconversion
by sex ( ) and year of seroconversion by IDU (P = .011 P =
). Owing to the presence of these interactions in the model,.007
the regression coefficients associated with the main effects in-
cluded in these interactions should be interpreted with caution.
Our objective was to study the impact of year of seroconversion
on the CD41 cell count slopes, and this effect can be obtained
for each sex by combining with IDU in the linear regression
model shown in table 3. The results are shown in table 4.
As shown in table 4, year of seroconversion was positively
associated with the CD41 cell count slope for men using in-
jection drugs ( cells/mm3 per semester) and negativelyb = 27.9
associated with the CD41 cell count slope for women not using
injection drugs ( cells/mm3 per semester). These resultsb = 217.6
mean that, after controlling for the initial CD41 cell count, the
rate of CD41 cell count loss is less important during the recent
years for men using injection drugs and more important during
the recent years for women not using injection drugs.
Discussion
The objective of this study was to explore the relationship
between the CD4 cell response early in the course of HIV in-
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Table 3. Multiple linear regression model relating individual CD41
cell count slopes to prognostic factors ( ).n = 68
Prognostic factor b 5 SE P 95% CI
Initial CD41 cell count 20.094 5 0.018 .000 20.130, 20.059
Female 75.1 5 24.0 .003 27.0, 123.1
Injection drug use 292.9 5 41.8 .030 2176.4, 29.4
Year of seroconversion 21.27 5 3.22 .694 27.72, 5.17
Interaction 1a 216.3 5 6.2 .011 228.7, 23.9
Interaction 2b 29.2 5 10.5 .007 8.2, 50.2
Constant 15.6 5 16.1 .337 216.7, 47.9
NOTE. CI, confidence interval.
a Year of seroconversion in relation to sex.
b Year of seconversion in relation to injection drug use.
Table 4. Effect of year of human immunodeficiency virus type 1
seroconversion on individual CD41 cell count slopes with respect to
each sex in combination with injection drug use (IDU).
b 5 SE 95% CI
No IDU
Men 21.27 5 3.22 27.72, 5.17
Women 217.6 5 5.5 228.6, 26.6
IDU
Men 27.9 5 10.1 7.7, 48.1
Women 11.6 5 11.5 211.4, 34.6
NOTE. CI, confidence interval.
fection and in the year of seroconversion among SHCS par-
ticipants who were free of antiretroviral treatment.
Linear analysis of the CD41 cell count within 2 years after
seroconversion showed interactions between the year of sero-
conversion and sex and IDU. This finding differed from those
of other studies [9, 18]. Our results are in the same direction
as those of Sinicco et al. [13] but are not completely similar.
Sinicco et al. [13] reported that the probability of the CD41
cell count falling to !500, !400, and cells/L and of6! 200 3 10
AIDS progression was higher for patients who seroconverted
after December 1989. Nevertheless, in our study, the significant
effect of the year of seroconversion was observed only through
the interaction terms, which do not seem to have been explored
in the Sinicco study. In our study, the year of seroconversion
had an effect among patients followed for 2 years with a similar
censoring strategy [19]. The main questions were the following:
(1) did we observe the emergence of HIV strains with various
levels of virulence in recent years; (2) is there any interaction
between the virus strain pathogenicity and the use of injection
drugs; and (3) is there any interaction between the virus strain
pathogenicity and the sex of the host? Fardzadegan et al. [20]
showed that women with the same virus load as men had 1.6-
fold higher risk of AIDS [20]. These results, combined with
ours, suggest that HIV pathogenicity might differ for males
and females and by route of HIV infection.
We do not have any information on the phenotype or ge-
notype of the virus strains, and little is known on the distri-
bution of those strains in different populations at risk of HIV
infection [21]. The phenotype defined by syncytium-inducing
strains is associated with a faster progression of disease [22],
but, until now, no particular genotype seemed to be associated
with a faster decrease in CD41 cell counts. For example, pri-
mary HIV infection by a strain with a mutation at codon 215,
which indicates acquired resistance to zidovudine, was not as-
sociated with more-severe clinical features [23, 24] or with a
faster loss of CD41 cells 1 year after HIV-1 infection [24]. There
is also little evidence that the viral subtype determines the rate
of disease progression among US patients [25], but HIV-1 sub-
types may differ in rates of progression to AIDS among female
sex workers in Senegal [26]. The host’s genetic status regarding
the CCR-5 chemokine receptor has been associated with var-
ious rates of progression [27, 28]. In particular, HIV-1–positive
patients who are heterozygous for the CCR-5 D32 deletion seem
to have a slower early HIV-1 progression [27, 28]. We did not
have this information for the SHCS participants; however, a
trend toward change of the genotype over time would be sur-
prising. This mutation alone does not explain the various rates
of HIV-1 disease progression [29], which can involve many fac-
tors [30–34].
Our study did have some limitations. Even with standardized
criteria of enrollment in the cohort, we cannot totally eliminate
recruitment bias toward inclusion of more severely ill patients
in recent years. Because the proportion of practitioners with
good experience in HIV medicine increased with time, they
could have referred to the university hospitals only the patients
with severe clinical features at seroconversion. Thus, since the
severity of acute HIV infection has been shown to be associated
with faster disease progression [35], our results could be biased
by a greater proportion of symptomatic seroconverters detected
in the recent years. Unfortunately, valid information on the
acute illness is not available in the Swiss cohort, especially for
patients who seroconverterted before 1990. Moreover, the pa-
tients who received antiretroviral treatment at primary HIV
infection and who were most likely to be recent seroconverters
were not analyzed, so that the study could be restricted to the
natural course of HIV infection.
The use of a standardized inclusion protocol and the absence
of statistical differences of major baseline characteristics be-
tween centers may not have prevented some factors, such as
genetic markers (i.e., the human major histocompatibility com-
plex genes HLA groups) associated with disease progression
[36], from being unequally distributed in Switzerland. The pro-
portion of patients who received an antiretroviral treatment
could have affected the results, but that proportion is expected
to be higher in the recent seroconverters. Thus, we should have
observed the opposite relationship between the year of sero-
conversion and the CD41 cell decrease. The new antiretroviral
therapy guidelines proposing to treat patients as early as pos-
sible after infection could definitively mask the natural history
of the CD41 cell response early in the course of infection among
patients with access to health care in the future [37].
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In summary, we found that the loss of CD41 cells was as-
sociated with the year of seroconversion by sex and IDU, sug-
gesting that the pathogenetic effect of HIV could have changed
since 1985 and differed by sex and route of HIV infection.
Physicians should be aware of this finding when estimating drug
efficacy. Moreover, if changes of HIV pathogenetic mechanisms
are confirmed, they can occur on targets other than CD41 cells
and need to be investigated.
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